Shares of Reata Pharmaceuticals were popping on Monday in after-hours trading as Wall Street learned that the company had achieved positive results from a clinical trial for a neuromuscular disorder treatment. Reata announced that compared to a palcebo, the mid-stage study of its treatment omaveloxolone significantly improved symptoms of Friedreich’s ataxia. Friedreich’s ataxia is a … Continue reading “Reata Pharmaceuticals Explodes as Company Meets Study Endpoint”
